The product side of health care includes drug and medical device manufacturers, as well as durable medical equipment and supplies. While a smaller portion of spending than health services, the product category has experienced more rapid spending growth, has high unit prices and profit margins and often has dubious proven value. Most of these items require a physician’s prescription to get used, so guess what, the industry spends a lot of effort trying to influence prescribing behavior. A study published in the Journal of the American Medical Association looks at how much was spent in 2015 in direct payments or delivery of items of value to doctors. (JAMA Study) The federal government created a national database of such payments and data from that database for 2015 was used to compare with physicians in the CMS database. The payments were lumped into three broad categories–general payments, research-related ones and ownership interests. 48% of doctors received some kind of payment from medical product manufacturers in 2015, with a total of $2.4 billion being disbursed, $1.8 billion of which represented general payments and only $75 million for research payments, which seems like the most legitimate value transfer. 89% of payments were in the form of food or beverage, but they represented a small portion of value. The most value, $484 million, was for royalty and license payments, followed by $472 million for services, like lectures. Physicians who do procedures, like surgeons and interventional cardiologists, received the most payments and value. 75% of cardiologists and 72% of gastroenterologists received payments. Surgeons got the majority of ownership interest payments. A higher percent of male physicians received a payment and the average amount received was higher than for female ones. And of course none of these payments in any manner was intended to, and almost certainly did not, influence physician use of the companies’ products. (LOL)
✅ Subscribe via Email
About this Blog
Healthy Skeptic Podcast
Research
MedPAC 2019 Report to Congress
June 18, 2019
Headlines
Tags
Access
ACO
Care Management
Chronic Disease
Comparative Effectiveness
Consumer Directed Health
Consumers
Devices
Disease Management
Drugs
EHRs
Elder Care
End-of-Life Care
FDA
Financings
Genomics
Government
Health Care Costs
Health Care Quality
Health Care Reform
Health Insurance
Health Insurance Exchange
HIT
HomeCare
Hospital
Hospital Readmissions
Legislation
M&A
Malpractice
Meaningful Use
Medicaid
Medical Care
Medicare
Medicare Advantage
Mobile
Pay For Performance
Pharmaceutical
Physicians
Providers
Regulation
Repealing Reform
Telehealth
Telemedicine
Wellness and Prevention
Workplace
Related Posts
Commentary
Karl Marx
February 10, 2025
Karl Marx
Karl Marx was essentially an idiot whose ideas have been adopted by totalitarians to justify…
Commentary
Debunking Climate Hysteria, February 9, 2025
February 9, 2025
Debunking Climate Hysteria, February 9, 2025
The latest in our irregular efforts to spread climate truth.
Commentary
Bob Dylan, Part 1
February 9, 2025
Bob Dylan, Part 1
A recent movie on Bob Dylan is worth a watch, but his songs are what…